Journey Medical Revenue Rises 8% on Emrosi Growth

Journey Medical Corporation reported third quarter 2026 results, with Emrosi sales up 84% year-over-year.

Updated on Nov. 12, 2026 in Economic Indicators

Journey Medical Revenue Rises 8% on Emrosi Growth

Journey Medical Corporation reported total revenues of $19.0 million for the third quarter of 2026, an 8% increase from the prior-year quarter. Emrosi generated $9.0 million in revenue, up 84% year-over-year, while the GAAP net loss narrowed to $1.3 million.

Why it matters

The results show Emrosi gaining ground in prescriptions and reimbursement mix, while overall profitability remains under pressure from operating costs. Cash and equivalents stood at $22.3 million at September 30, 2026, below the $24.1 million reported at year-end 2025.

The company reported total revenues of $19.0 million and Emrosi revenues of $9.0 million for the quarter, with approximately 40,000 Emrosi prescriptions dispensed. Whether the 84% Emrosi growth rate will hold in coming quarters is not addressed in the results.

The players

Journey Medical Corporation

Journey Medical Corporation is a Scottsdale, Arizona-based pharmaceutical company focused on dermatology products, including Emrosi.

The details

Growth in Emrosi was attributed to rising prescription demand and a better mix of prescriptions reimbursed by health plans, along with more unique prescribers writing for the product. SG&A rose $0.5 million to $12.6 million, primarily because of a one-time $1.7 million expense tied to resolving a dispute with a former vendor, partly offset by lower launch spending.

Timeline

  1. September 30, 2026: Third quarter 2026 period ended and results reported.

  2. November 12, 2026, 4:30 p.m. ET: Conference call and audio webcast on the results.

Economic Indicators

Compared with its own third quarter 2025 results, Journey Medical's net loss narrowed from $2.3 million to $1.3 million while revenue rose 8%, indicating a continued improvement trajectory. Whether that improvement widens into sustained profitability depends on future quarters not yet reported.

For patients and prescribers, the growth in Emrosi prescriptions and health plan reimbursement mix suggests broader access to the product. The results do not indicate any change in pricing for consumers.

The takeaway

Revenue growth paired with a narrowing loss shows the company moving toward profitability, but the one-time vendor expense makes the underlying cost trend harder to read. Investors should watch whether Emrosi prescription growth continues in upcoming quarters.

Further reading

Track broader trends in Economic Indicators across the United States.